



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

4 August 2020

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

MELBOURNE - Imagination Biosystems Limited (ASX: IBX) (the **Company**) gives notice that, on 4 August 2020 the Company issued 112,111,111 fully paid ordinary shares (**Shares**) as well as 6,500,000 Listed Options (**Options**) (exercisable at \$0.03 expiring on or before 28th April 2023) as part of the Placement announced to ASX on the 29th July 2020 and as part of lead manager agreement.

The Company issued the Shares and Options above without a disclosure document to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (**Act**).

Notice under Section 708A(5)(e) of the Act

The Company hereby gives notice that:

1. the Company issued the shares without disclosure to investors under Part 6D.2 of the Act;
2. this notice is being given under section 708A(5)(e) of the Act;
3. as at the date of this notice the Company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - b. section 674 of the Act; and
4. as at the date of this notice, there is no information that is “excluded information” within the meaning of Sections 708A(7) and 708A(8) of the Act.

-ENDS

About Imagination Biosystems

Imagination Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagination Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

This Announcement has been approved by the Board of Imagination Biosystems Limited

For further information please visit www.imaginationbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImaginationBiosystems@we-worldwide.com
+61-3-9866-4722